The biopharma buffer market is estimated to be valued at US$ 3.44 billion in 2022 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

 

Market Overview:

Biopharma buffers play a critical role in purification and downstream processing of biologics. They help in maintaining optimum pH range required by cells and biomolecules during various bioprocesses like cell culture, chromatography, analytical techniques etc. Common buffers used include phosphate, tris and histidine buffers depending on the application. They help stabilize biological molecules, proteins and cellular processes.

 

Market Dynamics:

The growth of the biopharma buffer market is majorly driven by increasing investments in biopharmaceutical R&D activities worldwide. Biopharmaceutical companies are investing heavily in developing complex biologics like monoclonal antibodies, recombinant proteins, gene and cell therapies which require extensive buffer usage during various stages of development and manufacturing. For instance, cell and gene therapy development requires optimized buffer solutions to maintain viability of cells during upstream and downstream processing. Additionally, rising prevalence of chronic diseases is also fueling demand for biologics which in turn is boosting consumption of buffers.
 

Segment Analysis

The global biopharma buffer market is segmented into product, compound, and end user. Based on the product, the market is divided into phosphate buffer, tris buffer, acetate buffer, citrate buffer and others. Among these, the phosphate buffer segment accounted for the largest market share in 2022 owing to its wide applications in protein purification, cell culture and blood collection. The segment is likely to continue its dominance over the forecast period due to ability of phosphate buffer to maintain pH in optimum range.

 

PEST Analysis

Political: The regulations by FDA and EMA to ensure effective buffers for biopharma production are expected to drive the demand. Economic: Increasing R&D investments by biopharma companies for developing novel biologics will augment the market revenue. Social: Rising awareness about biopharma buffers for ensuring efficacy of final biologic products will positively influence the demand. Technological: Continuous advancements in buffer formulation and screening technologies are helping manufacturers optimize buffer selection and composition.

 

Key Takeaways

The Global Biopharma Buffer Market Size  is expected to witness high growth, exhibiting CAGR of 7.1% over the forecast period, due to increasing demand for monoclonal antibodies and recombinant proteins. Regionally, North America dominated the market and accounted for over 35% share in 2022 led by the presence of large biopharma industry and rising development of biosimilars. Europe was the second largest market in 2022 driven by expanding research infrastructure. Key players operating in the biopharma buffer market are Merck KGaA, Thermo Fisher Scientific Inc., Avantor, Inc., Lonza Group Ltd., Bio-Rad Laboratories, Inc., Sartorius AG, Corning Inc., Becton, Dickinson and Company, GE Healthcare, Promega Corporation

The global biopharma buffer market size was valued at US$ 3.44 billion in 2022. The market is driven by increasing demand for monoclonal antibodies and recombinant proteins in disease therapeutics and diagnostics. North America dominated the regional segment in 2022 owing to presence of large biopharmaceutical industry and rising development of biosimilars in the region. Europe captured the second largest market share in 2022 led by expanding research infrastructure in the region.

Key players operating in the biopharma buffer market include Merck KGaA, Thermo Fisher Scientific Inc., Avantor, Inc., Lonza Group Ltd., Bio-Rad Laboratories, Inc. Merck KGaA captured the largest market share in 2022 owing to its wide buffer product portfolio and global footprint across major markets. Lonza Group Ltd. and Thermo Fisher Scientific Inc. followed next in terms of revenue generation.
 

Read More -  https://www.newsanalyticspro.com/biopharma-buffer-market-share-demand-analysis-size-and-forecast/